“The Truth Is, We Must Miss Some”: A Qualitative Study of the Patient Eligibility Screening Process, and Automation Perspectives, for Cancer Clinical Trials
Cancer Medicine · 2024-12 · 13 (23)
DOI: 10.1002/cam4.70466 ↗Kurz gefasst
Qualitative Studie in der Zeitschrift Cancer Medicine, online erschienen am 03.12.2024. Verfasst von A La Rosa und 8 weiteren Autor:innen. Beteiligte Einrichtung: Laboratoire d'Informatique Médicale et d'Ingénierie des Connaissances Pour la e-Santé, LIMICS, Sorbonne University, Inserm, Université Sorbonne Paris…. Hauptthemen laut MEDLINE: Patient Selection, Neoplasms, Qualitative Research, Clinical Trials as Topic. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Société Française d'Oto-Rhino-Laryngologie et de Chirurgie de la Face et du Cou.
Abstract (Originalsprache)
Background
Recruitment of cancer patients into clinical trials (CTs) is a challenge. We aimed to explore how patient eligibility assessment is conducted in practice, what factors support or hinder this process, and to assess the potential usefulness of Clinical Trial Recruitment Support Systems (CTRSS) for patient‐to‐trial matching.
Methods
We conducted semi‐structured interviews in France with healthcare professionals involved in cancer CTs and experts on trial recruitment. We focused on the stages in‐between trial feasibility, and patient information and consent. Interviews were recorded, and the transcripts were analyzed thematically. We used the Systems Engineering Initiative for Patient Safety (SEIPS) 2.0 framework to organize our results.
Results
We interviewed 25 participants. We identified common steps for cancer patient eligibility assessment: prescreening under medical supervision, followed by the validation of patient‐trial matching based on manual chart review. This process built on rich interactions between clinicians, other professionals (clinical research assistants, data scientists, medical coding experts), and patients. Technological factors, mainly related to data infrastructure (both for patient data and trial data), and organizational factors (research culture, incentives, formal and informal research networks) mediated the performance of the recruitment process. Participants had mixed feelings towards CTRSSs; they welcomed automated pre‐screening but insisted on manual verification. Given the necessary collaborative nature of multisite trials, coordinated efforts to support a common data infrastructure could be helpful.
Conclusions
Material, organizational, and human factors affect cancer patient eligibility assessment for CTs. Patient‐to‐trial matching tools bear potential, but good understanding of the ecosystem, including stakeholders' motivations, is a prerequisite.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Laboratoire d'Informatique Médicale et d'Ingénierie des Connaissances Pour la e-Santé, LIMICS, Sorbonne University, Inserm, Université Sorbonne Paris Nord, Paris, Cedex, France.
- LTSI-UMR 1099, Université de Rennes, CHU de Rennes, Rennes, France.
- LTSI-UMR 1099, Université de Rennes, CLCC Eugène Marquis, Rennes, France.
- Department of Medical Oncology, Henri Mondor and Albert Chenevier Teaching Hospital, Université Paris Est Créteil, Assistance Publique-Hôpitaux de Paris, Creteil, France.
- Department of Otorhinolaryngology-Head and Neck Surgery, Sorbonne University, Assistance Publique-Hôpitaux de Paris, Tenon Hospital, Paris Cedex, France.
- Laboratoire de Génie Industriel, CentraleSupélec-Paris-Saclay Campus, Gif Sur Yvette, France.
Förderung
- Société Française d'Oto-Rhino-Laryngologie et de Chirurgie de la Face et du Cou
Zitieren
APA
La Rosa, A., Vaterkowski, M., Cuggia, M., Campillo-Gimenez, B., Tournigand, C., Baujat, B., Daniel, C., Kempf, E., & Lamé, G. (2024). “The Truth Is, We Must Miss Some”: A Qualitative Study of the Patient Eligibility Screening Process, and Automation Perspectives, for Cancer Clinical Trials. Cancer Medicine, 13(23). https://doi.org/10.1002/cam4.70466
Vancouver
La Rosa A, Vaterkowski M, Cuggia M, Campillo-Gimenez B, Tournigand C, Baujat B, et al. “The Truth Is, We Must Miss Some”: A Qualitative Study of the Patient Eligibility Screening Process, and Automation Perspectives, for Cancer Clinical Trials. Cancer Medicine. 2024;13(23). doi:10.1002/cam4.70466
BibTeX
@article{LaRosa2024,
author = {La Rosa, A and Vaterkowski, M and Cuggia, M and Campillo-Gimenez, B and Tournigand, C and Baujat, B and Daniel, C and Kempf, E and Lamé, G},
title = {“The Truth Is, We Must Miss Some”: A Qualitative Study of the Patient Eligibility Screening Process, and Automation Perspectives, for Cancer Clinical Trials},
journal = {Cancer Medicine},
year = {2024},
volume = {13},
number = {23},
doi = {10.1002/cam4.70466}
}
EUVIMED